Aurora Cannabis is enhancing its medical offerings. The company is expanding in Australia and New Zealand. They are introducing new cannabis products. This includes THC flower and resin cartridges. The expansion aims to give patients more choice. It also ensures high quality. Access to science-backed cannabis improves.
New Zealand will receive new THC flower strains. Big Wave™ is one of them. It is a hybrid strain. It contains 26% THC. Night Ride™ is another new strain. This one is Indica. It has 29% THC. Both launch this month. Half Moon™, a balanced strain, is coming soon. It is expected in Q1 FY27. This balanced option offers a different profile. It contains 9% THC and 13% CBD.
Australia will see four new resin cartridges. Chemango™ Kush is one. Cosmic Cream™ is another. Lunar Express™ and Soul Train Haze™ complete the lineup. These product launches reinforce Aurora’s presence. They cater to specific patient preferences. These new cannabis products arrive as part of a broader strategy.
Aurora leverages its proprietary genetics. The company develops these unique strains. Manufacturing occurs in Canada. Aurora’s facilities hold EU-GMP and TGA-GMP certifications. This is critical for quality assurance. These standards ensure pharmaceutical-grade production. Safety and consistency are paramount.
Australia is a vital international market for Aurora. The company considers it a top priority. New Zealand is equally important. Aurora reaffirms its commitment to both regions. Patient needs are constantly evolving. The company adapts by offering diverse product formats. Reliable supply chains are essential for patient care.
Stanley Sack, Interim Managing Director of MedReleaf Australia, commented. He highlighted Aurora’s dedication. He also noted the growing demands of healthcare professionals. The company strives to support better patient outcomes. Its focus remains on quality and dependable supply. This ensures patients get the products they need.
These new cannabis products represent a significant step. They expand Aurora’s medical portfolio. They align with its global growth strategy. The company focuses on high-margin medical markets. This approach offers stability. It also ensures profitability. Aurora is a leading global medical cannabis company. It aims to serve patients effectively.
The expansion in Australia and New Zealand is strategic. It strengthens Aurora’s market position. It provides more therapeutic options. Patients will benefit from greater choice. They will also have better access to quality cannabis. Aurora continues its mission. It delivers science-backed cannabis globally.
